Unity Biotechnology, Inc. Doses First Patients in Phase 2 As

UNITY Biotechnology, Inc. announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325 , a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF...

Related Keywords

, Unity Biotechnology Inc , Best Corrected Visual Acuity , Markets ,